CASE REPORT

Watery diarrhea, hypokalemia and achlorhydria syndrome due to an adrenal pheochromocytoma

Shin-ichi Ikuta, Chiaki Yasui, Masahiro Kawanaka, Tsukasa Aihara, Hidenori Yoshie, Hidenori Yanagi, Masao Mitsunobu, Ayako Sugihara, Naoki Yamanaka

Shin-ichi Ikuta, Chiaki Yasui, Tsukasa Aihara, Hidenori Yoshie, Hidenori Yanagi, Masao Mitsunobu, Naoki Yamanaka, Department of Surgery, Meiwa General Hospital, Hyogo 663-8186, Japan
Masahiro Kawanaka, Department of Internal Medicine, Meiwa General Hospital, Hyogo 663-8186, Japan
Ayako Sugihara, Department of Pathology, Meiwa General Hospital, Hyogo 663-8186, Japan
Correspondence to: Shin-ichi Ikuta, Department of Surgery, Meiwa General Hospital, Agenaru 4-31, Nishinomiya, Hyogo 663-8186, Japan
Telephone: +81-798-471767 Fax: +81-798-477613
Received: 2007-05-15 Accepted: 2007-06-09

Abstract

Watery diarrhea, hypokalemia and achlorhydria (WDHA) syndrome caused by vasoactive intestinal polypeptide (VIP) -producing tumor only rarely occurs in patients with nonpancreatic disease. A 49-year-old woman was referred for evaluation of a right adrenal tumor incidentally diagnosed by abdominal ultrasound during the investigation of chronic watery diarrhea. Laboratory findings showed hypokalemia and excessive production of VIP and catecholamines. After surgical resection of the tumor, diarrhea subsided and both electrolytes and affected hormone levels normalized. Immunohistochemical examination confirmed a diagnosis of pheochromocytoma, which was immunohistochemically confirmed to contain immunoreactive VIP. After surgical resection of the tumor, hypokalemia due to a right adrenal pheochromocytoma, which was immunohistochemically confirmed to contain immunoreactive VIP. After surgical resection of the tumor, symptoms completely disappeared and the preoperatively elevated plasma VIP level normalized.

CASE REPORT

A 49-year-old woman was referred to our hospital for evaluation of a right adrenal tumor. For several years, she had experienced protracted episodes of watery diarrhea, up to 6 times in 24 h, without blood or mucus. In the course of evaluating the diarrhea, an abdominal ultrasound was performed by her primary physician and a right adrenal tumor was incidentally discovered. She had no history of headache, palpitation, perspiration or hypertension. She also had no relevant familial history of endocrine disease. Her height was 150 cm and weight 46.8 kg. Physical examination showed blood pressure of 110/67 mmHg and regular heart rate of 70 beats/min. Laboratory tests showed hypokalemia of 3.1 mEq/L. Fasting blood sugar was 179 mg/dL and a 75-g oral glucose tolerance test (75-g OGTT) showed a pattern indicating diabetes mellitus. Results of complete blood cell count and other routine biochemical tests were within normal ranges. An abdominal computed tomography (CT) scan demonstrated a mass measuring 6 cm in diameter in the right adrenal region, but there was no apparent abnormality in the pancreas (Figure 1A). Magnetic resonance imaging (MRI) of the pituitary fossa was normal.

We then performed an endocrinological evaluation. Examination of plasma hormone levels demonstrated elevated concentrations of VIP, epinephrine, norepinephrine and dopamine (Table 1). In addition, 24-h urinary catecholamines were also highly elevated, confirming the presence of a pheochromocytoma. Plasma cortisol, gastrin, glucagon, adrenocorticotropic hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, growth...
hormone, thyroxine, parathyroid hormone and calcitonin levels were within normal ranges.

Based on these results, the patient was diagnosed as having an adrenal pheochromocytoma with excessive catecholamine production and WDHA syndrome due to the excessive secretion of VIP, probably produced by the pheochromocytoma.

She subsequently underwent surgical resection of the tumor. At laparotomy, the tumor was found above the upper pole of the right kidney and was separated from the pancreas. Right adrenalectomy was accomplished without complications except for a transient elevation of systolic blood pressure up to 190 mmHg during manipulation of the tumor.

The patient had an uneventful postoperative course. The diarrhea soon subsided, and the laboratory data demonstrated normalization of plasma potassium level and improvement in glucose tolerance. The postoperative plasma levels of VIP and catecholamines as well as the 24-h urinary excretion of catecholamines were markedly decreased (Table 1). At follow-up 12 mo after surgery, the patient was well without any signs of recurrence.

The tumor weighed 65 g and measured 6 cm × 7 cm. It was encased in a brownish capsule and contained a normal adrenal cortex attached to the upper part. The cut surface showed variegated white and red-brown areas, typical of a pheochromocytoma (Figure 1B). Histologically, large polygonal cells with eosinophilic granular cytoplasm were arranged in alveolar and anastomosing trabecular patterns invested by a fine fibrovascular stroma. Tumor cells showed prominent nucleoli and were strongly positive for chromogranin A and WDHA syndrome (Figure 1C). There were no ganglioneuromatous figures. We then looked for the presence of VIP-positive cells. VIP immunoreactivity was found in some of the ganglion-like cells scattered among the predominant neoplastic cell population (Figure 1D).

The WDHA syndrome is, although rare, a well-defined clinicopathologic entity that occurs most often in association with VIP-producing tumor. VIP is a 28-amino acid peptide that stimulates intestinal water and electrolyte secretion by activating adenylate cyclase and cyclic AMP in intestinal cells. It is physiologically distributed in the digestive tract, the central and peripheral nervous systems, as well as in the adrenals. VIP also inhibits gastric acid secretion, promotes hepatic glycogenolysis and hyperglycemia, and dilates peripheral systemic blood vessels. When it is secreted in large amounts from endocrine tumors, the patient typically experiences massive secretory diarrhea, dehydration, flushing and weight loss. Characteristic laboratory abnormalities include hypokalemia, achlorhydria, hypercalcemia, hyperglycemia and metabolic acidosis. Unfortunately, we did not perform gastric analysis for acid secretion in our patient. However, it is now known that achlorhydria

**DISCUSSION**

The WDHA syndrome is a rare but distinctive clinicopathologic entity that occurs most often in association with VIP-producing tumor. VIP is a 28-amino acid peptide that stimulates intestinal water and electrolyte secretion by activating adenylate cyclase and cyclic AMP in intestinal cells. It is physiologically distributed in the digestive tract, the central and peripheral nervous systems, as well as in the adrenals. VIP also inhibits gastric acid secretion, promotes hepatic glycogenolysis and hyperglycemia, and dilates peripheral systemic blood vessels. When it is secreted in large amounts from endocrine tumors, the patient typically experiences massive secretory diarrhea, dehydration, flushing and weight loss. Characteristic laboratory abnormalities include hypokalemia, achlorhydria, hypercalcemia, hyperglycemia and metabolic acidosis. Unfortunately, we did not perform gastric analysis for acid secretion in our patient. However, it is now known that achlorhydria

**Table 1 Pre- and post-operative hormone levels**

|                      | Pre-operative | Post-operative |
|----------------------|---------------|----------------|
| Plasma VIP, pg/mL (100) | 225           | 7              |
| Plasma catecholamines, ng/mL |             |               |
| Epinephrine (0.070) | 2.22          | 0.028          |
| Norepinephrine (0.06-0.46) | 1.81         | 1.53           |
| Dopamine (0.014) | 0.609         | 0.03           |
| 24-h urinary catecholamines, ng/d |               |               |
| Epinephrine (1-29) | 4890          | 4              |
| Norepinephrine (26-230) | 920          | 154            |
| Dopamine (310-1140) | 209000        | 474            |

Normal range is given in parentheses.
is not necessarily part of the WDHA syndrome and that hypochlorhydria or even normal acid secretion may occur.

To our knowledge, fifteen cases of pheochromocytoma associated with the WDHA syndrome have been reported since the first report in 1975 by Loehy et al. Ten cases were histologically diagnosed as pheochromocytoma while five cases were diagnosed as mixed pheochromocytoma-ganglioneuroma. In the cases of mixed pheochromocytoma-ganglioneuroma, immunoreactive VIP was confined to the ganglion cells of the ganglioneuroma component, whereas the pheochromocytes did not show staining for VIP. Eckhout et al. documented a pheochromocytoma in which VIP was seen only in scattered cells among pheochromocytes, as in our case. In contrast, other investigators have found VIP-positivity in the pheochromocytes themselves.

The differences in these immunohistochemical findings have been partly explained by the neuronal differentiation of neoplastic cells. Both chromaffin cells and ganglion cells are derived from the neural crest and have in common a number of histochemical and biosynthetic characteristics, including amine precursor uptake and decarboxylation (APUD). Sano et al. suggested that tumor cells of hormone-producing neurogenic tumors can be divided into at least two cell populations: adrenergic neuron-related cells containing catecholamine and somatostatin, and cholinergic neuron-related cells containing VIP. Matsuoka et al. demonstrated in an experimental study that some factors in glioma-conditioned medium induced the cholinergic neuronal differentiation of rat pheochromocytes. Mendelsohn et al. immunohistochemically identified isolated VIP-containing cells that showed distinct ganglion cell differentiation in two of four pheochromocytomas without associated diarrhea. However, since pheochromocytes lacking ganglionic differentiation features may stain for VIP, it has been postulated that neoplastic transformation might elicit VIP synthesis by the tumor cells. This could be consistent with the knowledge that neoplastic growth of APUD cells may produce several polypeptides or amines, which are characteristic not only of their specific differentiated cell types but also of associated APUD cells derived from the common neuroectoderm.

An interesting feature of this case was the absence of any hypertensive symptoms characteristic of pheochromocytoma. Most patients with pheochromocytoma complicated by WDHA syndrome remain normotensive despite high catecholamine levels. A certain proportion of patients with pheochromocytoma are indeed clinically “silent”, but, in our case, it is conceivable that VIP might have masked the symptoms of catecholamine overproduction by either its vasodilator effect or subsequent induction of secretory diarrhea and dehydration.

This case is an unusual presentation of pheochromocytoma in which diarrhea was the principal clinical sign. We suggest that, in a patient with chronic diarrhea of unknown etiology, it is important to perform not only gastrointestinal investigations but also abdominal ultrasound and/or CT scan to determine if a mass is present. When an adrenal mass is discovered, determination of catecholamines, as well as VIP is essential for a precise diagnosis even if the clinical symptoms are not characteristic of pheochromocytoma.

ACKNOWLEDGMENTS

We acknowledge the contributions of Dr. Kurimoto to the diagnosis and management of this patient.

REFERENCES

1. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958; 25: 374-380
2. Bloom SR, Polak JM, Pearse AG. Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet 1973; 2: 14-16
3. Said SI. Evidence for secretion of vasoactive intestinal peptide by tumours of pancreas, adrenal medulla, thyroid and lung: support for the unifying APUD concept. Clin Endocrinol (Oxf) 1976; 5: Suppl: 2015-2045
4. Schwartz CJ, Kimberg DV, Sheinin HE, Field M, Said SI. Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa. J Clin Invest 1974; 54: 536-544
5. Schmid KW, Dockhorn-Dworniczak B, Fahrenkamp A, Kirchmair R, Tötsch M, Fischer-Colbrie R, Böcker W, Winkler H. Chromogranin A, secretogranin II and vasoactive intestinal peptide in pheochromocytomas and ganglioneuromas. Histopathology 1993; 22: 527-533
6. Sackel SG, Manson JE, Harawi SJ, Burakoff R. Watery diarrhea syndrome due to an adrenal pheochromocytoma secreting vasoactive intestinal polypeptide. Dig Dis Sci 1985; 30: 1201-1207
7. Smith SI, Slappy AL, Fox TP, Scolapio JS. Pheochromocytoma; producing vasoactive intestinal peptide. Mayo Clin Proc 2002; 77: 97-100
8. Fahrenkrug J. Vasoactive intestinal polypeptide. Clin Gastroenterol 1980; 9: 633-643
9. Loehry CA, Kingham JG, Whorwell PJ. Watery diarrhoea and hypokalaemia associated with a pheochromocytoma. Postgrad Med J 1975; 51: 416-419
10. Cooperman AM, Desantis D, Winkelman E, Farmer R, Eversman J, Said S. Watery diarrhea syndrome. Two unusual cases and further evidence that VIP is a humoral mediator. Am Surg 1978; 44: 325-328
11. Matta MK, Prorok JJ, Trimpi HD, Sheats J, Stasik JJ, Khubchandani IT. WDHA syndrome caused by pheochromocytoma: a report of a case. Dis Colon Rectum 1978; 21: 297-301
12. Pais SO. Angiographic demonstration of a vasoactive intestinal polypeptide-secreting pheochromocytoma in a patient with WDHA syndrome. AJR Am J Roentgenol 1978; 130: 172-174
13. Viale G, Dell’Orto P, Moro E, Cozzaglio L, Coggi G. Vasoactive intestinal polypeptide-, somatostatin-, and calcitonin-producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings. Cancer 1985; 55: 1109-1116
14. Fisher BM, MacPhee GJ, Davies DL, McPherson SG, Brown IL, Goldberg A. A case of watery diarrhoea syndrome due to an adrenal pheochromocytoma secreting vasoactive intestinal polypeptide with coincidental autoimmune thyroid disease. Acta Endocrinol (Copenh) 1987; 114: 340-344
15. Quarelis Van Ufford-Mannesse P, Castro Cabezás M, Vroom TM, Van Gils A, Lips CJ, Niemeijer P. A patient with neurofibromatosis type I and watery diarrhea syndrome due to a VIP-producing adrenal pheochromocytoma. J Intern Med 1999; 246: 231-234
16. Van Eckhout P, Shungu H, Descamps FX, Lanthier P, Castelain T, Saey JP, Rettman R, Dresc C, Colin IM. Acute watery diarrhea
as the initial presenting feature of a pheochromocytoma in an 84-year-old female patient. *Horm Res* 1999; 52: 101-106

17 Trump DL, Livingston JN, Baylin SB. Watery diarrhea syndrome in an adult with ganglioneuroma-pheochromocytoma: identification of vasoactive intestinal peptide, calcitonin, and catecholamines and assessment of their biologic activity. *Cancer* 1977; 40: 1526-1532

18 Nigawara K, Suzuki T, Tazawa H, Funyu T, Yagihashi S, Yamaya K, Terayama Y, Yamaguchi K. A case of recurrent malignant pheochromocytoma complicated by watery diarrhea, hypokalemia, achlorhydria syndrome. *J Clin Endocrinol Metab* 1987; 65: 1053-1056

19 Salmi J, Pelto-Huikko M, Auvinen O, Karvonen AL, Saaristo J, Paronen I, Pöyhönen L, Seppänen S. Adrenal pheochromocytoma-ganglioneuroma producing catecholamines and various neuropeptides. *Acta Med Scand* 1988; 224: 403-408

20 Contreras LN, Budd D, Yen TS, Thomas C, Tyrrell JB. Adrenal ganglioneuroma-pheochromocytoma secreting vasoactive intestinal polypeptide. *West J Med* 1991; 154: 334-337

21 Onozawa M, Fukushima T, Minoguchi M, Takahata M, Yamamoto Y, Miyake T, Kanagawa K, Kanda M, Maekawa I. Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1. *Jpn J Clin Oncol* 2005; 35: 559-563

22 Pearse AG, Polak JM. Endocrine tumours of neural crest origin: neurolophomas, apudomas and the APUD concept. *Med Biol* 1974; 52: 3-18

23 Sano T, Saito H, Inaba H, Hizawa K, Saito S, Yamanoi A, Mizunuma Y, Matsumura M, Yuasa M, Hiraishi K. Immunoreactive somatostatin and vasoactive intestinal polypeptide in adrenal pheochromocytoma. An immuno-chemical and ultrastructural study. *Cancer* 1983; 52: 282-289

24 Matsuoka I, Satake R, Kurihara K. Cholinergic differentiation of clonal rat pheochromocytoma cells (PC12) induced by factors contained in glioma-conditioned medium: enhancement of high-affinity choline uptake system and reduction of norepinephrine uptake system. *Brain Res* 1986; 389: 145-152

25 Mendelsohn G, Eggleston JC, Olson JL, Said SI, Baylin SB. Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. *Lab Invest* 1979; 41: 144-149

26 Weichert RF. The neural ectodermal origin of the peptide-secreting endocrine glands. A unifying concept for the etiology of multiple endocrine adenomatosis and the inappropriate secretion of peptide hormones by nonendocrine tumors. *Am J Med* 1970; 49: 232-241

27 Melicow MM. One hundred cases of pheochromocytoma (107 tumors) at the Columbia-Presbyterian Medical Center, 1926-1976: a clinicopathological analysis. *Cancer* 1977; 40: 1987-2004